Skip to main navigation Skip to search Skip to main content

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

  • on behalf of the YOSEMITE and RHINE Investigators

Research output: Contribution to journal › Article › peer-review

18   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Agricultural and Biological Sciences

Immunology and Microbiology